Eliem Therapeutics Inc (ELYM)
7.47
-0.40
(-5.08%)
USD |
NASDAQ |
May 23, 16:00
7.47
0.00 (0.00%)
After-Hours: 16:15
Eliem Therapeutics Shareholders Equity (Quarterly): 106.38M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 106.38M |
December 31, 2023 | 107.60M |
September 30, 2023 | 109.74M |
June 30, 2023 | 112.50M |
March 31, 2023 | 116.86M |
December 31, 2022 | 128.72M |
September 30, 2022 | 134.36M |
Date | Value |
---|---|
June 30, 2022 | 142.24M |
March 31, 2022 | 155.14M |
December 31, 2021 | 167.20M |
September 30, 2021 | 176.66M |
June 30, 2021 | 101.91M |
March 31, 2021 | 49.62M |
December 31, 2020 | 21.57M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
21.57M
Minimum
Dec 2020
176.66M
Maximum
Sep 2021
116.46M
Average
114.68M
Median
Shareholders Equity (Quarterly) Benchmarks
Alpine Immune Sciences Inc | 332.70M |
Candel Therapeutics Inc | 5.979M |
Cyclacel Pharmaceuticals Inc | -2.206M |
Lipocine Inc | 23.96M |
GlycoMimetics Inc | 28.91M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 109.33M |
Total Liabilities (Quarterly) | 2.95M |